{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:05:20Z","timestamp":1792847120614,"version":"4.5.0"},"reference-count":124,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mary Overton postdoctoral fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Acquisition<\/jats:title>\n                    <jats:p>We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal\/biliary events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae719","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T15:47:18Z","timestamp":1728575238000},"page":"1-15","source":"Crossref","is-referenced-by-count":160,"title":["Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-4771","authenticated-orcid":false,"given":"Ryan J","family":"Jalleh","sequence":"first","affiliation":[{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital , Adelaide, SA 5000 ,","place":["Australia"]},{"name":"Adelaide Medical School, The University of Adelaide , Adelaide, SA 5000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9640-1911","authenticated-orcid":false,"given":"Mark P","family":"Plummer","sequence":"additional","affiliation":[{"name":"Adelaide Medical School, The University of Adelaide , Adelaide, SA 5000 ,","place":["Australia"]},{"name":"Intensive Care Unit, Royal Adelaide Hospital , Adelaide, SA 5000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8086-2449","authenticated-orcid":false,"given":"Chinmay S","family":"Marathe","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital , Adelaide, SA 5000 ,","place":["Australia"]},{"name":"Adelaide Medical School, The University of Adelaide , Adelaide, SA 5000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8959-5239","authenticated-orcid":false,"given":"Mahesh M","family":"Umapathysivam","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital , Adelaide, SA 5000 ,","place":["Australia"]},{"name":"Adelaide Medical School, The University of Adelaide , Adelaide, SA 5000 ,","place":["Australia"]},{"name":"Southern Adelaide Diabetes and Endocrine Service, Flinders Medical Centre , Bedford Park, SA 5042 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4357-6846","authenticated-orcid":false,"given":"Daniel R","family":"Quast","sequence":"additional","affiliation":[{"name":"Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, Sankt Josef-Hospital, Ruhr-University , D-44791 Bochum ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5527-256X","authenticated-orcid":false,"given":"Christopher K","family":"Rayner","sequence":"additional","affiliation":[{"name":"Adelaide Medical School, The University of Adelaide , Adelaide, SA 5000 ,","place":["Australia"]},{"name":"Department of Gastroenterology and Hepatology, Royal Adelaide Hospital , Adelaide, SA 5000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1155-5816","authenticated-orcid":false,"given":"Karen L","family":"Jones","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital , Adelaide, SA 5000 ,","place":["Australia"]},{"name":"Adelaide Medical School, The University of Adelaide , Adelaide, SA 5000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1656-9210","authenticated-orcid":false,"given":"Tongzhi","family":"Wu","sequence":"additional","affiliation":[{"name":"Adelaide Medical School, The University of Adelaide , Adelaide, SA 5000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0942-0306","authenticated-orcid":false,"given":"Michael","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital , Adelaide, SA 5000 ,","place":["Australia"]},{"name":"Adelaide Medical School, The University of Adelaide , Adelaide, SA 5000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-6954","authenticated-orcid":false,"given":"Michael A","family":"Nauck","sequence":"additional","affiliation":[{"name":"Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, Sankt Josef-Hospital, Ruhr-University , D-44791 Bochum ,","place":["Germany"]},{"name":"Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald , D-17475 Greifswald ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"issue":"2","key":"2025071012512707700_dgae719-B1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.diabres.2012.08.002","article-title":"Guideline for management of postmeal glucose in diabetes","volume":"103","author":"International Diabetes Federation Guideline Development Group","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"2025071012512707700_dgae719-B2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2337\/dc16-2380","article-title":"Basal glucose can be controlled, but the prandial problem persists- it\u2019s the next target","volume":"40","author":"Riddle","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"2025071012512707700_dgae719-B3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"issue":"11","key":"2025071012512707700_dgae719-B4","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.2337\/dc11-0102","article-title":"Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control","volume":"34","author":"Downie","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"2025071012512707700_dgae719-B5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2337\/dc08-1671","article-title":"Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial","volume":"32","author":"Raz","year":"2009","journal-title":"Diabetes Care"},{"issue":"9","key":"2025071012512707700_dgae719-B6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/BF00400362","article-title":"Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects","volume":"36","author":"Horowitz","year":"1993","journal-title":"Diabetologia"},{"key":"2025071012512707700_dgae719-B7","first-page":"1643","article-title":"Gastric emptying in early noninsulin-dependent diabetes mellitus","volume":"37","author":"Jones","year":"1996","journal-title":"J Nucl Med"},{"issue":"9","key":"2025071012512707700_dgae719-B8","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1210\/JC.2015-2482","article-title":"Relationships of early and late glycemic responses with gastric emptying during an oral glucose tolerance test","volume":"100","author":"Marathe","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025071012512707700_dgae719-B9","doi-asserted-by":"crossref","first-page":"752329","DOI":"10.3389\/fendo.2021.752329","article-title":"The 1-hour plasma glucose: common link across the glycemic spectrum","volume":"12","author":"Bergman","year":"2021","journal-title":"Front Endocrinol"},{"issue":"3","key":"2025071012512707700_dgae719-B10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1023\/A:1022528414264","article-title":"Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients","volume":"48","author":"Gonlachanvit","year":"2003","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2025071012512707700_dgae719-B11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/dom.13604","article-title":"A whey\/guar \u201cpreload\u201d improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: a 12-week, single-blind, randomized, placebo-controlled trial","volume":"21","author":"Watson","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2025071012512707700_dgae719-B12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man","volume":"38","author":"Wettergren","year":"1993","journal-title":"Dig Dis Sci"},{"issue":"3","key":"2025071012512707700_dgae719-B13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.50.3.341","article-title":"Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans","volume":"50","author":"Schirra","year":"2002","journal-title":"Gut"},{"issue":"5","key":"2025071012512707700_dgae719-B14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/gut.46.5.622","article-title":"Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans","volume":"46","author":"Schirra","year":"2000","journal-title":"Gut"},{"issue":"5","key":"2025071012512707700_dgae719-B15","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"issue":"5","key":"2025071012512707700_dgae719-B16","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2005-2220","article-title":"Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses","volume":"91","author":"Little","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071012512707700_dgae719-B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1210\/jc.2009-1503","article-title":"Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia","volume":"95","author":"Deane","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025071012512707700_dgae719-B18","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/diacare.24.8.1416","article-title":"Glucagon-like peptide-1 infusion must be maintained for 24\u2005hours\/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment","volume":"24","author":"Larsen","year":"2001","journal-title":"Diabetes Care"},{"issue":"5","key":"2025071012512707700_dgae719-B19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"issue":"2","key":"2025071012512707700_dgae719-B20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/db13-0893","article-title":"Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia","volume":"63","author":"Umapathysivam","year":"2014","journal-title":"Diabetes"},{"key":"2025071012512707700_dgae719-B21","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al \u00a02024. JCEM 2024 Online Supplement. figshare. 10.6084\/m9.figshare.26540737.v1. Journal contribution."},{"issue":"10","key":"2025071012512707700_dgae719-B22","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1111\/dom.14477","article-title":"Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes","volume":"23","author":"Quast","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1-3","key":"2025071012512707700_dgae719-B23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2008.07.003","article-title":"Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes","volume":"151","author":"Linnebjerg","year":"2008","journal-title":"Regul Pept"},{"issue":"1","key":"2025071012512707700_dgae719-B24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2337\/db15-0893","article-title":"The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial","volume":"65","author":"Thazhath","year":"2016","journal-title":"Diabetes"},{"key":"2025071012512707700_dgae719-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2013.04.001","article-title":"Effects of lixisenatide once daily on gastric emptying in type 2 diabetes\u2013relationship to postprandial glycemia","volume":"185","author":"Lorenz","year":"2013","journal-title":"Regul Pept"},{"issue":"5","key":"2025071012512707700_dgae719-B26","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/dom.13633","article-title":"Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes","volume":"21","author":"Jones","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2025071012512707700_dgae719-B27","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3390\/nu12071962","article-title":"Acute effects of lixisenatide on energy intake in healthy subjects and patients with type 2 diabetes: relationship to gastric emptying and intragastric distribution","volume":"12","author":"Jalleh","year":"2020","journal-title":"Nutrients"},{"issue":"2","key":"2025071012512707700_dgae719-B28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","article-title":"Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes","volume":"97","author":"Horowitz","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"2025071012512707700_dgae719-B29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S2468-1253(17)30285-6","article-title":"Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial","volume":"2","author":"Halawi","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"2025071012512707700_dgae719-B30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/oby.23941","article-title":"Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide","volume":"32","author":"Camilleri","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"2025071012512707700_dgae719-B31","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1111\/dom.14166","article-title":"Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying","volume":"22","author":"Horowitz","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"9645","key":"2025071012512707700_dgae719-B32","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"2025071012512707700_dgae719-B33","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/dom.14373","article-title":"Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes","volume":"23","author":"Dahl","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2025071012512707700_dgae719-B34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","article-title":"Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity","volume":"20","author":"Hjerpsted","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2025071012512707700_dgae719-B35","doi-asserted-by":"crossref","first-page":"0136618","DOI":"10.1371\/journal.pone.0136618","article-title":"Paracetamol as a post prandial marker for gastric emptying, a food-drug interaction on absorption","volume":"10","author":"Bartholome","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"2025071012512707700_dgae719-B36","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/dom.14110","article-title":"The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists","volume":"22","author":"Urva","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2025071012512707700_dgae719-B37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrendo.2014.202","article-title":"Gastric emptying and glycaemia in health and diabetes mellitus","volume":"11","author":"Phillips","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2025071012512707700_dgae719-B38","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/0016-5085(95)90202-3","article-title":"The [13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals","volume":"108","author":"Braden","year":"1995","journal-title":"Gastroenterol"},{"issue":"4","key":"2025071012512707700_dgae719-B39","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0016-5085(97)70126-4","article-title":"[13c] octanoic acid breath test for gastric emptying of solids: accuracy, reproducibility, and comparison with scintigraphy","volume":"112","author":"Choi","year":"1997","journal-title":"Gastroenterol"},{"issue":"9","key":"2025071012512707700_dgae719-B40","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2337\/dc20-0720","article-title":"Effects of lixisenatide versus liraglutide (short- and long-acting GLP-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes","volume":"43","author":"Quast","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"2025071012512707700_dgae719-B41","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1055\/a-1784-6185","article-title":"Measurement of gastric emptying using a 13C-octanoic acid breath test with wagner-Nelson analysis and scintigraphy in type 2 diabetes","volume":"130","author":"Trahair","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"2025071012512707700_dgae719-B42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/apt.17856","article-title":"Review article: pharmacologic management of obesity\u2014updates on approved medications, indications and risks","volume":"59","author":"Lupianez-Merly","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2025071012512707700_dgae719-B43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2337\/dc17-1536","article-title":"Gastrointestinal symptoms in diabetes: prevalence, assessment, pathogenesis, and management","volume":"41","author":"Du","year":"2018","journal-title":"Diabetes Care"},{"issue":"11","key":"2025071012512707700_dgae719-B44","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.7326\/M23-2019","article-title":"Accurate measurements of gastric emptying and gastrointestinal symptoms in the evaluation of glucagon-like peptide-1 receptor agonists","volume":"176","author":"Jalleh","year":"2023","journal-title":"Ann Intern Med"},{"issue":"3","key":"2025071012512707700_dgae719-B45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00265086","article-title":"Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus","volume":"32","author":"Horowitz","year":"1989","journal-title":"Diabetologia"},{"issue":"4","key":"2025071012512707700_dgae719-B46","doi-asserted-by":"crossref","first-page":"534","DOI":"10.5056\/jnm19060","article-title":"Association between symptoms, quality of life, and gastric emptying in dyspeptic patients","volume":"25","author":"Wuestenberghs","year":"2019","journal-title":"J Neurogastroenterol Motil"},{"issue":"12","key":"2025071012512707700_dgae719-B47","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/MNM.0b013e32834bf262","article-title":"Clinical significance of scintigraphic rapid gastric emptying","volume":"32","author":"Balan","year":"2011","journal-title":"Nucl Med Commun"},{"issue":"12","key":"2025071012512707700_dgae719-B48","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00125-022-05796-1","article-title":"Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control","volume":"65","author":"Jalleh","year":"2022","journal-title":"Diabetologia"},{"issue":"6","key":"2025071012512707700_dgae719-B49","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1053\/j.gastro.2019.03.030","article-title":"Is making the stomach pump better the answer to gastroparesis?","volume":"156","author":"Rayner","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"2025071012512707700_dgae719-B50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ajcn\/66.1.127","article-title":"Relation between postprandial satiation and antral area in normal subjects","volume":"66","author":"Jones","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"2025071012512707700_dgae719-B51","doi-asserted-by":"crossref","first-page":"111091","DOI":"10.1016\/j.jclinane.2023.111091","article-title":"Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy","volume":"87","author":"Silveira","year":"2023","journal-title":"J Clin Anesth"},{"key":"2025071012512707700_dgae719-B52","first-page":"A756","article-title":"Glucagon-like peptide (GLP)-1(7-36)-amide: a central suppressor of food intake in rats (abstract)","volume":"102","author":"Schick","year":"1992","journal-title":"Gastroenterol"},{"issue":"6560","key":"2025071012512707700_dgae719-B53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"issue":"3","key":"2025071012512707700_dgae719-B54","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"issue":"3","key":"2025071012512707700_dgae719-B55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41366-021-01043-6","article-title":"Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist","volume":"46","author":"Shoemaker","year":"2022","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"2025071012512707700_dgae719-B56","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4\u2005mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025071012512707700_dgae719-B57","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.metabol.2018.03.017","article-title":"Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: a randomized, double-blind, placebo-controlled trial","volume":"85","author":"Basolo","year":"2018","journal-title":"Metabolism"},{"issue":"6","key":"2025071012512707700_dgae719-B58","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"2025071012512707700_dgae719-B59","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2337\/dc12-1925","article-title":"Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity","volume":"36","author":"Schl\u00f6gl","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"2025071012512707700_dgae719-B60","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/dom.14050","article-title":"Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes","volume":"22","author":"Dub\u00e9","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2025071012512707700_dgae719-B61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.14255","article-title":"Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes","volume":"23","author":"Gibbons","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2025071012512707700_dgae719-B62","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4093\/dmj.2019.0018","article-title":"Glucagon-like peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in lean and obese individuals with type 2 diabetes mellitus","volume":"44","author":"Bae","year":"2020","journal-title":"Diabetes Metab J"},{"issue":"10","key":"2025071012512707700_dgae719-B63","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dom.12108","article-title":"The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment","volume":"15","author":"Flint","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"4-5","key":"2025071012512707700_dgae719-B64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0031-9384(88)90333-2","article-title":"Gastric distension and gastric capacity in relation to food intake in humans","volume":"44","author":"Geliebter","year":"1988","journal-title":"Physiol Behav"},{"issue":"3","key":"2025071012512707700_dgae719-B65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/ajcn\/48.3.592","article-title":"Gastric distention by balloon and test-meal intake in obese and lean subjects","volume":"48","author":"Geliebter","year":"1988","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"2025071012512707700_dgae719-B66","doi-asserted-by":"crossref","first-page":"e131429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"10","key":"2025071012512707700_dgae719-B67","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"2025071012512707700_dgae719-B68","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight","volume":"124","author":"Baggio","year":"2014","journal-title":"J Clin Invest"},{"key":"2025071012512707700_dgae719-B69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/B978-0-12-800263-6.00003-3","article-title":"Apolipoprotein B-48: a unique marker of chylomicron metabolism","volume":"64","author":"Nakajima","year":"2014","journal-title":"Adv Clin Chem"},{"issue":"12","key":"2025071012512707700_dgae719-B70","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs","volume":"53","author":"Rehfeld","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"1-3","key":"2025071012512707700_dgae719-B71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2012.08.005","article-title":"Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects","volume":"179","author":"Keller","year":"2012","journal-title":"Regul Pept"},{"issue":"10","key":"2025071012512707700_dgae719-B72","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/jcph.940","article-title":"Effect of albiglutide on cholecystokinin-induced gallbladder emptying in healthy individuals: a randomized crossover study","volume":"57","author":"Shaddinger","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"2025071012512707700_dgae719-B73","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/dom.13420","article-title":"Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity","volume":"20","author":"Nexoe-Larsen","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2025071012512707700_dgae719-B74","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"2025071012512707700_dgae719-B75","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/ATVBAHA.121.316311","article-title":"GLP-1 (glucagon-like peptide-1) is physiologically relevant for chylomicron secretion beyond its known pharmacological role","volume":"41","author":"Nahmias","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2025071012512707700_dgae719-B76","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"issue":"9","key":"2025071012512707700_dgae719-B77","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","article-title":"Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes","volume":"49","author":"Matikainen","year":"2006","journal-title":"Diabetologia"},{"issue":"12","key":"2025071012512707700_dgae719-B78","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.12359","article-title":"Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes","volume":"16","author":"Tremblay","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2025071012512707700_dgae719-B79","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1210\/jc.2018-01176","article-title":"Lixisenatide reduces chylomicron triacylglycerol by increased clearance","volume":"104","author":"Whyte","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025071012512707700_dgae719-B80","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/dom.14328","article-title":"Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes","volume":"23","author":"Taskinen","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2025071012512707700_dgae719-B81","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11883-022-00982-3","article-title":"The effect of GLP-1 receptor agonists on postprandial lipaemia","volume":"24","author":"Novodvorsky","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"2025071012512707700_dgae719-B82","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/dom.15365","article-title":"Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes","volume":"26","author":"Mather","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2025071012512707700_dgae719-B83","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2982.2007.01079.x","article-title":"GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome","volume":"20","author":"Hellstr\u00f6m","year":"2008","journal-title":"Neurogastroenterol Motil"},{"issue":"5","key":"2025071012512707700_dgae719-B84","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","article-title":"Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy","volume":"43","author":"Nakatani","year":"2017","journal-title":"Diabetes Metab"},{"issue":"3","key":"2025071012512707700_dgae719-B85","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025071012512707700_dgae719-B86","first-page":"G 920","article-title":"Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms","volume":"273","author":"Imeryuz","year":"1997","journal-title":"Am J Physiol"},{"issue":"1","key":"2025071012512707700_dgae719-B87","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db15-0973","article-title":"Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia","volume":"65","author":"Krieger","year":"2016","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"2025071012512707700_dgae719-B88","doi-asserted-by":"crossref","first-page":"MON-681","DOI":"10.1210\/jendso\/bvaa046.609","article-title":"MON-681 dulaglutide commonly known as trulicity; an anti-diabetic medication causing small bowel obstruction","volume":"4","author":"Gandhi","year":"2020","journal-title":"J Endocr Soc"},{"issue":"3","key":"2025071012512707700_dgae719-B89","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"issue":"4","key":"2025071012512707700_dgae719-B90","doi-asserted-by":"crossref","first-page":"A2334","DOI":"10.1016\/j.chest.2023.07.1569","article-title":"A rare case of a large bowel obstruction due to tirzepatide","volume":"164","author":"Gordon","year":"2023","journal-title":"Chest"},{"issue":"1","key":"2025071012512707700_dgae719-B91","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cpt.2430","article-title":"Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes","volume":"111","author":"Faillie","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2025071012512707700_dgae719-B92","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.therap.2020.02.024","article-title":"Incretin-based drugs and intestinal obstruction: a pharmacovigilance study","volume":"75","author":"Gudin","year":"2020","journal-title":"Therapie"},{"issue":"11","key":"2025071012512707700_dgae719-B93","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","article-title":"Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA adverse event reporting system database","volume":"42","author":"Wu","year":"2022","journal-title":"Clin Drug Investig"},{"key":"2025071012512707700_dgae719-B94","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"18","key":"2025071012512707700_dgae719-B95","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"2025071012512707700_dgae719-B96","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cgh.2023.08.034","article-title":"Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: scandinavian cohort study","volume":"22","author":"Ueda","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2025071012512707700_dgae719-B97","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s13340-016-0261-3","article-title":"Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study","volume":"7","author":"Bennett","year":"2016","journal-title":"Diabetol Int"},{"key":"2025071012512707700_dgae719-B98","doi-asserted-by":"crossref","first-page":"279530","DOI":"10.1155\/2011\/279530","article-title":"Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function","volume":"2011","author":"Marathe","year":"2011","journal-title":"Exp Diabetes Res"},{"issue":"8","key":"2025071012512707700_dgae719-B99","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.2337\/db13-1627","article-title":"Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin","volume":"63","author":"Wu","year":"2014","journal-title":"Diabetes"},{"issue":"4","key":"2025071012512707700_dgae719-B100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.gie.2024.04.2900","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients","volume":"100","author":"Nadeem","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"2025071012512707700_dgae719-B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.013","article-title":"Clinical outcomes and safety of upper endoscopy while on glucagon-like peptide-1 receptor agonists","volume":"22","author":"Firkins","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2025071012512707700_dgae719-B102","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/jdi.14005","article-title":"Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy","volume":"14","author":"Kobori","year":"2023","journal-title":"J Diabetes Investig"},{"key":"2025071012512707700_dgae719-B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2024.05.012","article-title":"Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during esophagogastroduodenoscopy","volume":"100","author":"Chapman","year":"2024","journal-title":"Gastrointest Endosc"},{"issue":"6","key":"2025071012512707700_dgae719-B104","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.14309\/ajg.0000000000002777","article-title":"Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: a case-control study","volume":"119","author":"Garza","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2025071012512707700_dgae719-B105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s10620-022-07536-2","article-title":"Retained food during esophagogastroduodenoscopy is a risk factor for gastric-to-pulmonary aspiration","volume":"68","author":"Feighery","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2025071012512707700_dgae719-B106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00000542-199301000-00010","article-title":"Clinical significance of pulmonary aspiration during the perioperative period","volume":"78","author":"Warner","year":"1993","journal-title":"Anesthesiology"},{"issue":"3","key":"2025071012512707700_dgae719-B107","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/jcem-68-3-647","article-title":"Comparison of the pattern of postprandial carbohydrate metabolism after ingestion of a glucose drink or a mixed meal","volume":"68","author":"McMahon","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025071012512707700_dgae719-B108","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1172\/JCI108740","article-title":"The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine","volume":"59","author":"Vantrappen","year":"1977","journal-title":"J Clin Invest"},{"key":"2025071012512707700_dgae719-B109","first-page":"631","volume-title":"Proceedings of the Fourth International Symposium on Gastrointestinal Motility","author":"Code","year":"1974"},{"issue":"7","key":"2025071012512707700_dgae719-B110","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s11695-024-07278-2","article-title":"Safe continuation of glucagon-like peptide 1 receptor agonists at endoscopy: a case series of 57 adults undergoing endoscopic sleeve gastroplasty","volume":"34","author":"Maselli","year":"2024","journal-title":"Obes Surg"},{"key":"2025071012512707700_dgae719-B111","doi-asserted-by":"crossref","first-page":"111365","DOI":"10.1016\/j.jclinane.2023.111365","article-title":"Preoperative ultrasound assessment of gastric content in patients with diabetes: a meta-analysis based on a systematic review of the current literature","volume":"93","author":"Baldawi","year":"2024","journal-title":"J Clin Anesth"},{"issue":"2","key":"2025071012512707700_dgae719-B112","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2024.03.015","article-title":"Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use","volume":"167","author":"Yeo","year":"2024","journal-title":"Gastroenterology"},{"key":"2025071012512707700_dgae719-B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.04.038","article-title":"Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes","volume":"22","author":"Barlowe","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2025071012512707700_dgae719-B114","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1111\/dom.15636","article-title":"Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists","volume":"26","author":"Klonoff","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"19","key":"2025071012512707700_dgae719-B115","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.2024.5003","article-title":"Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications","volume":"331","author":"Dixit","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"2025071012512707700_dgae719-B116","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PRS.0b013e3181de24bc","article-title":"Identifying and avoiding bias in research","volume":"126","author":"Pannucci","year":"2010","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"2025071012512707700_dgae719-B117","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/ALN.0000000000004776","article-title":"ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists","volume":"140","author":"Ushakumari","year":"2024","journal-title":"Anesthesiology"},{"issue":"2","key":"2025071012512707700_dgae719-B118","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/db13-0805","article-title":"Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and \u201cisoglycemic\u201d intravenous glucose","volume":"63","author":"Vardarli","year":"2014","journal-title":"Diabetes"},{"issue":"11","key":"2025071012512707700_dgae719-B119","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2025071012512707700_dgae719-B120","author":"American Gastroenterological Association"},{"issue":"11","key":"2025071012512707700_dgae719-B121","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/anae.16117","article-title":"Pre-operative gastric ultrasound in patients at risk of pulmonary aspiration: a prospective observational cohort study","volume":"78","author":"Baettig","year":"2023","journal-title":"Anaesthesia"},{"issue":"6","key":"2025071012512707700_dgae719-B122","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamasurg.2024.0111","article-title":"Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia","volume":"159","author":"Sen","year":"2024","journal-title":"JAMA Surg"},{"issue":"7","key":"2025071012512707700_dgae719-B123","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.2337\/diabetes.54.7.2212","article-title":"Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects","volume":"54","author":"Meier","year":"2005","journal-title":"Diabetes"},{"issue":"2","key":"2025071012512707700_dgae719-B124","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/00365529509093252","article-title":"Comparison between physiologic and erythromycin-induced interdigestive motility","volume":"30","author":"Bj\u00f6rnsson","year":"1995","journal-title":"Scand J Gastroenterol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae719\/60038965\/dgae719.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/1\/1\/61213682\/dgae719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/1\/1\/61213682\/dgae719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T16:51:44Z","timestamp":1752166304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/1\/1\/7824836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,17]]},"published-print":{"date-parts":[[2024,12,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae719","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,17]]}}}